source
- Akeso's ivonescimab shows survival advantage over Keytruda in Chinese lung cancer trialA new data cut from a study comparing ivonescimab, a bispecific antibody from China-based Akeso, with Merck's Keytruda in patients with non-small cell lung cancer was released. The interim results…
- CBER official overturns Replimune melanoma drug rejection; AbbVie reports phase 3 success in multiple myelomaA CBER regulator has reversed a prior decision to reject Replimune's experimental melanoma therapy, allowing the program to move forward. AbbVie announced that its multiple myeloma candidate achie…